The Second Act of Biotech
Pfizer sells dopamine. Moderna made the COVID vaccine. Both are betting their next decade on medicines that barely existed when their stocks peaked...
Moderna Inc. (MRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Theleme Partners Patrick Degorce | 8,057,571 | $564,271,697 | +1% | 33.52% |
| 2. | 3,026,200 | $211,924,786 | -16% | 0.02% | |
| 3. | 2,911,800 | $203,913,354 | -3% | 0.02% | |
| 4. | BAMCO Inc. Ron Baron | 1,989,386 | $139,316,702 | 0.21% | |
| 5. | 1,943,700 | $136,117,311 | +131% | 0.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 57,493 | $1,812,754.29 | 9,210,686 | 2025-03-03 | Filing | |
| $31.04 | 102,821 | $3,191,563.84 | 9,153,193 | 2025-03-03 | Filing | |
| $31.76 | 31,620 | $1,004,251.20 | 312,027 | 2025-03-03 | Filing | |
| $19.00 | 52,631 | $999,989.00 | 420,407 | 2020-02-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $146.07 | 40,281 | $5,883,845.67 | 1,562,029 | 2026-09-15 | Filing | |
| $144.13 | 40,294 | $5,807,574.22 | 1,525,858 | 2026-09-14 | Filing | |
| $134.49 | 15,000 | $2,017,350.00 | 59,375 | 2026-09-10 | Filing | |
| $134.49 | 19,836 | $2,667,743.64 | 74,375 | 2026-09-10 | Filing | |
| $139.95 | 3,471 | $485,766.45 | 74,129 | 2026-09-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 51,859,891 | $3,631,748,191 | 0.16% | |
| 2. | 30,599,409 | $2,142,876,625 | 0.03% | |
| 3. | 23,208,792 | $1,625,311,704 | 0.03% | |
| 4. | 22,276,996 | $1,560,053,964 | 0.18% | |
| 5. | 18,206,778 | $1,275,020,663 | 1.16% |
News See All
Cathie Wood Buys $3.6M of HOOD, Sells $2.9M of 2 High-Growth Stocks – September 5
Cathie Wood-led ARK Invest made several notable trades on Friday, September 4, with Robinhood Markets ($HOOD), an online brokerage and financial-se...
Moderna Stock (MRNA) Drops as Rothschild Downgrades to ‘Sell’ on Valuation Concerns
Moderna ($MRNA) stock was down about 3% in Thursday’s pre-market trading after Rothschild Redburn analyst Simon Baker downgraded his rating on the ...
Jim Cramer Explains Why Heavily Shorted Moderna (MRNA) Has Room to Run
During the August 31 episode of Mad Money, Jim Cramer addressed shifting market dynamics, highlighting how the fallout from heavily crowded hedge fund positions was finally unwinding.
Moderna Stock (MRNA) Was the Best Performer in August
The pharma company’s share price soared on news of a cancer drug breakthrough.
Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck's Trial Results Encouraging
August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least.
Healthcare's Best Week Since June Traces Back to a Single Moderna and Merck Cancer Trial
The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in...
BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why
BioNTech ($BNTX) shares declined as much as 10% on Friday after the company said it has ended a key Phase 2 trial for its mRNA colorectal cancer va...
Moderna (MRNA) Plans $2B of Zero-Coupon Convertible Debt. Is the Capped Call Enough to Control Dilution?
Moderna, Inc. (NASDAQ:MRNA) proposed a private placement of $2.0 billion in convertible senior notes due in 2032, with an option for initial purchasers to acquire another $300 million.